Patents by Inventor Galia Temtsin Krayz
Galia Temtsin Krayz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11844859Abstract: Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.Type: GrantFiled: November 19, 2020Date of Patent: December 19, 2023Assignee: Nasus Pharma Ltd.Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
-
Publication number: 20230105615Abstract: Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, comprising an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition comprising solid particles of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.Type: ApplicationFiled: March 16, 2021Publication date: April 6, 2023Inventors: Galia Temtsin-Krayz, Pavel Kazhdan
-
Patent number: 11400045Abstract: Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, having an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition having solid particles of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.Type: GrantFiled: December 28, 2020Date of Patent: August 2, 2022Assignee: Nasus Pharma Ltd.Inventors: Galia Temtsin-Krayz, Pavel Kazhdan
-
Patent number: 11331270Abstract: The present application relates to a pharmaceutical composition in a form of dry powder for intranasal administration, comprising solid particles of at least one active agent and solid particles of a diluent, said pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein said pharmaceutical composition having at least 90% of the particles of said at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of said at least one active agent with a mean particle size equal to or below 5 microns. The particles of said diluent have a mean particle size of 30-200 microns. The present application also relates to an apparatus and modified spray drying method for preparation of the pharmaceutical composition of the present invention in the dry powder form.Type: GrantFiled: August 19, 2018Date of Patent: May 17, 2022Assignee: Nasus Pharma Ltd.Inventor: Galia Temtsin-Krayz
-
Patent number: 11202757Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.Type: GrantFiled: December 1, 2020Date of Patent: December 21, 2021Assignee: Formulex Pharma Innovations Ltd.Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
-
Publication number: 20210283050Abstract: Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, having an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition having solid particles of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.Type: ApplicationFiled: December 28, 2020Publication date: September 16, 2021Inventors: Galia Temtsin-Krayz, Pavel Kazhdan
-
Publication number: 20210283074Abstract: A composition in the form of dry powder for intranasal administration, having solid particles, each having a physiologically acceptable mucoadhesive polymer in combination with at least one functional additive such as pH adjusting agent, with at least about 90% of the particles having a size of about 25-300 microns, and various prophylactic and preventive uses thereof.Type: ApplicationFiled: December 15, 2020Publication date: September 16, 2021Inventors: Tair Lapidot, Galia Temtsin-Krayz, Carolina Abrutzky, Dalia Megiddo
-
Patent number: 11116723Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.Type: GrantFiled: November 30, 2020Date of Patent: September 14, 2021Assignee: Formulex Pharma Innovations Ltd.Inventor: Galia Temtsin-Krayz
-
Publication number: 20210128462Abstract: Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.Type: ApplicationFiled: November 19, 2020Publication date: May 6, 2021Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
-
Publication number: 20210077392Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.Type: ApplicationFiled: November 30, 2020Publication date: March 18, 2021Inventor: Galia Temtsin-Krayz
-
Publication number: 20210077390Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone.Type: ApplicationFiled: December 1, 2020Publication date: March 18, 2021Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
-
Publication number: 20200368156Abstract: The present application relates to a pharmaceutical composition in a form of dry powder for intranasal administration, comprising solid particles of at least one active agent and solid particles of a diluent, said pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein said pharmaceutical composition having at least 90% of the particles of said at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of said at least one active agent with a mean particle size equal to or below 5 microns. The particles of said diluent have a mean particle size of 30-200 microns. The present application also relates to an apparatus and modified spray drying method for preparation of the pharmaceutical composition of the present invention in the dry powder form.Type: ApplicationFiled: August 19, 2018Publication date: November 26, 2020Applicant: Formulex Pharma Innovations Ltd.Inventor: Galia Temtsin-Krayz
-
Publication number: 20170119660Abstract: A pharmaceutical composition is provided for transmucosal administration of an active lipophilic compound through the oral mucosa comprising a lipophilic active compound, a polymeric matrix formed by two or more water-soluble polymers and a rapid dissolution agent. At least one of the water-soluble polymers is an amphiphilic polymer and at least one is either a hydrophilic polymer or an amphiphilic polymer with a hydrophobic-hydrophilic balance different from the first amphiphilic polymer. In addition, the polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the lipophilic active compound, which is interwoven with the aforesaid polymeric matrix.Type: ApplicationFiled: October 28, 2016Publication date: May 4, 2017Inventors: Galia TEMTSIN-KRAYZ, Sabina GLOZMAN, Pavel KAZHDAN
-
Publication number: 20160220505Abstract: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.Type: ApplicationFiled: February 8, 2016Publication date: August 4, 2016Inventors: Galia TEMTSIN KRAYZ, Maryana AVERBUCH, Ilya ZELKIND, Larisa GITIS
-
Patent number: 9254268Abstract: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.Type: GrantFiled: September 25, 2008Date of Patent: February 9, 2016Assignee: SOLUBEST LTD.Inventors: Galia Temtsin Krayz, Maryana Averbuch, Ilya Zelkind, Larisa Gitis
-
Publication number: 20090098200Abstract: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.Type: ApplicationFiled: September 25, 2008Publication date: April 16, 2009Applicant: SOLUBEST LTD.Inventors: Galia Temtsin Krayz, Maryana Averbuch, Ilya Zelkind, Larisa Gitis